Indonesia, April 20 -- Taipei (ANTARA/PRNewswire)- ACT Genomics today announced a significant upgrade to the ACTDrug(R) series, its next-generation sequencing (NGS) genomic profiling service. The updated panel now covers 101 clinically relevant genes and offers a seven-working-day turnaround time, designed to provide comprehensive genomic information to support physicians in making treatment decision for newly diagnosed patients with advanced or metastatic cancer.

The upgraded ACTDrug(R) series is designed to deliver timely, actionable genomic insights at the time of diagnosis and initial treatment planning, when early treatment decisions can significantly impact patient outcomes. With broader gene coverage and faster reporting, clinicia...